BioCentury | Oct 13, 2020
Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

...company expects to meet with regulators and consider a path forward based on its findings.The TITAN...
BioCentury | Jun 9, 2020
Finance

Regeneron joins $100M round for DNAnexus to support global growth

...investors GV, Foresite Capital Management LLC, TPG Capital and First Round Capital. DNAnexus’ Apollo and Titan...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

...soon follow, as both the Phase III ARCHES trial of Xtandi and the Phase III TITAN...
...Placebo + prednisone (n=602) NA 14.8 36.5 Johnson & Johnson (NYSE:JNJ) Erleada apalutamide Ph III TITAN...
...co-primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) in the Phase III TITAN...
BioCentury | Feb 1, 2019
Clinical News

J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

...an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN...
...approval of the second-generation androgen receptor antagonist in the indication are expected this year. On TITAN's...
BioCentury | Jan 30, 2019
Clinical News

J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

...an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN...
...approval of the second-generation androgen receptor antagonist in the indication are expected this year. On TITAN's...
BioCentury | Sep 14, 2018
Company News

ICER finds opioid use disorder treatments not cost-effective

...marketed buprenorphine products -- once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and implant Probuphine from Titan Pharmaceuticals Inc....
...lost $0.60 to $40.09 on Sept. 10, while Indivior was up 8.60p to 268.30p and Titan...
...Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Braeburn Pharmaceuticals Inc., Princeton, N.J. Indivior plc (LSE:INDV), Richmond, Va. Titan Pharmaceuticals Inc....
BioCentury | Sep 10, 2018
Company News

ICER finds opioid use disorder treatments are not cost-effective

...marketed buprenorphine products -- once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and implant Probuphine from Titan Pharmaceuticals Inc....
...Alkermes lost $0.60 to $40.09 on Monday, while Indivior was up 8.60p to 268.30p and Titan...
...buprenorphine Sublocade (Brand), RBP-6000 (Compound #), buprenorphine (Generic) Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX) Alkermes plc Braeburn Pharmaceuticals Inc. Indivior plc Titan Pharmaceuticals Inc. ICER MATs medication-assisted...
BioCentury | May 4, 2018
Company News

ICER to consider broad outcomes for buprenorphines

...products -- the once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and the implant Probuphine from Titan Pharmaceuticals Inc....
...England Comparative Effectiveness Public Advisory Council (CEPAC) on Nov. 8. Indivior plc (LSE:INDV), Richmond, Va. Titan Pharmaceuticals Inc....
...NASDAQ:TTNP), South San Francisco, Calif. Braeburn Pharmaceuticals Inc., Princeton, N.J. Business: Neurology Mary Romeo CAM2038 Probuphine Sublocade Suboxone Vivitrol Braeburn Pharmaceuticals Inc. Indivior plc Titan Pharmaceuticals Inc....
BioCentury | Apr 27, 2018
Politics & Policy

ICER to consider broad outcomes for buprenorphines

...products -- the once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and the implant Probuphine from Titan Pharmaceuticals Inc....
...England Comparative Effectiveness Public Advisory Council (CEPAC) on November 8. Mary Romeo CAM2038 Methadone Probuphine Sublocade Suboxone sublingual film Vivitrol Braeburn Pharmaceuticals Inc. Indivior plc Titan Pharmaceuticals Inc....
BioCentury | Apr 6, 2018
Company News

ICER to evaluate buprenorphines for opioid disorder

...with a transmucosal buprenorphine-containing product. It also markets Suboxone sublingual film to treat opioid dependence. Titan Pharmaceuticals Inc....
...and to prevent relapse to opioid dependence following opioid detoxification. Indivior plc (LSE:INDV), Richmond, Va. Titan Pharmaceuticals Inc....
...Compound #), buprenorphine (Generic) Suboxone sublingual film, buprenorphine/naloxone Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX) Alkermes plc Braeburn Pharmaceuticals Inc. Indivior plc Titan Pharmaceuticals Inc. ICER Institute...
Items per page:
1 - 10 of 299
BioCentury | Oct 13, 2020
Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

...company expects to meet with regulators and consider a path forward based on its findings.The TITAN...
BioCentury | Jun 9, 2020
Finance

Regeneron joins $100M round for DNAnexus to support global growth

...investors GV, Foresite Capital Management LLC, TPG Capital and First Round Capital. DNAnexus’ Apollo and Titan...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

...soon follow, as both the Phase III ARCHES trial of Xtandi and the Phase III TITAN...
...Placebo + prednisone (n=602) NA 14.8 36.5 Johnson & Johnson (NYSE:JNJ) Erleada apalutamide Ph III TITAN...
...co-primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) in the Phase III TITAN...
BioCentury | Feb 1, 2019
Clinical News

J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

...an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN...
...approval of the second-generation androgen receptor antagonist in the indication are expected this year. On TITAN's...
BioCentury | Jan 30, 2019
Clinical News

J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

...an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN...
...approval of the second-generation androgen receptor antagonist in the indication are expected this year. On TITAN's...
BioCentury | Sep 14, 2018
Company News

ICER finds opioid use disorder treatments not cost-effective

...marketed buprenorphine products -- once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and implant Probuphine from Titan Pharmaceuticals Inc....
...lost $0.60 to $40.09 on Sept. 10, while Indivior was up 8.60p to 268.30p and Titan...
...Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Braeburn Pharmaceuticals Inc., Princeton, N.J. Indivior plc (LSE:INDV), Richmond, Va. Titan Pharmaceuticals Inc....
BioCentury | Sep 10, 2018
Company News

ICER finds opioid use disorder treatments are not cost-effective

...marketed buprenorphine products -- once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and implant Probuphine from Titan Pharmaceuticals Inc....
...Alkermes lost $0.60 to $40.09 on Monday, while Indivior was up 8.60p to 268.30p and Titan...
...buprenorphine Sublocade (Brand), RBP-6000 (Compound #), buprenorphine (Generic) Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX) Alkermes plc Braeburn Pharmaceuticals Inc. Indivior plc Titan Pharmaceuticals Inc. ICER MATs medication-assisted...
BioCentury | May 4, 2018
Company News

ICER to consider broad outcomes for buprenorphines

...products -- the once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and the implant Probuphine from Titan Pharmaceuticals Inc....
...England Comparative Effectiveness Public Advisory Council (CEPAC) on Nov. 8. Indivior plc (LSE:INDV), Richmond, Va. Titan Pharmaceuticals Inc....
...NASDAQ:TTNP), South San Francisco, Calif. Braeburn Pharmaceuticals Inc., Princeton, N.J. Business: Neurology Mary Romeo CAM2038 Probuphine Sublocade Suboxone Vivitrol Braeburn Pharmaceuticals Inc. Indivior plc Titan Pharmaceuticals Inc....
BioCentury | Apr 27, 2018
Politics & Policy

ICER to consider broad outcomes for buprenorphines

...products -- the once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and the implant Probuphine from Titan Pharmaceuticals Inc....
...England Comparative Effectiveness Public Advisory Council (CEPAC) on November 8. Mary Romeo CAM2038 Methadone Probuphine Sublocade Suboxone sublingual film Vivitrol Braeburn Pharmaceuticals Inc. Indivior plc Titan Pharmaceuticals Inc....
BioCentury | Apr 6, 2018
Company News

ICER to evaluate buprenorphines for opioid disorder

...with a transmucosal buprenorphine-containing product. It also markets Suboxone sublingual film to treat opioid dependence. Titan Pharmaceuticals Inc....
...and to prevent relapse to opioid dependence following opioid detoxification. Indivior plc (LSE:INDV), Richmond, Va. Titan Pharmaceuticals Inc....
...Compound #), buprenorphine (Generic) Suboxone sublingual film, buprenorphine/naloxone Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX) Alkermes plc Braeburn Pharmaceuticals Inc. Indivior plc Titan Pharmaceuticals Inc. ICER Institute...
Items per page:
1 - 10 of 299